international team has found a new pathway in NK cells that leads to the
rejection of metastatic tumors.1 It is still unclear which
components of the pathway will make the best targets.
Tackling the targets
Researchers had mixed views on whether CBL-B itself or the
TAM receptors are better targets. Some companies have a head start on the
latter family with programs against AXL.
A. SciBX 7(10); doi:10.1038/scibx.2014.274 published online March 13, 2014
1. Paolino, M. et al. Nature; published online Feb. 19,
2014; doi:10.1038/nature12998 Contact: Josef M. Penninger, Institute of Molecular
Biotechnology of the Austrian Academy of Sciences, Vienna, Austria e-mail: email@example.com
2. Bachmaier, K. et al. Nature 403, 211-216 (2000)
3. Loeser, S. et al. J. Exp. Med. 204, 879-891 (2007)
4. Rosell, R. et al. Lancet 382, 720-731 (2013)
5. Zhang, Z. et al. Nat. Genet. 44, 852-860 (2012)
6. Zhang, Y.-X. et al. Cancer Res. 68, 1905-1915 (2008)
7. Gjerdrum, C. et al. Proc. Natl. Acad. Sci. USA 107, 1124-1129 (2010)
M.J. SciBX 1(11); doi:10.1038/scibx.2008.250
Apeiron Biologics AG, Vienna, Austria
Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y.
Institute of Molecular Biotechnology of the Austrian
Academy of Sciences, Vienna,
Lead Discovery Center GmbH, Dortmund, Germany
Max Planck Institute of Biochemistry, Martinsried, Germany
Medical University Innsbruck, Innsbruck, Austria
Chapel Hill, N.C.
Qurient Co. Ltd.,
Seongnam, South Korea
Rigel Pharmaceuticals Inc. (NASDAQ:RIGL), South San Francisco, Calif.
Tolero Pharmaceuticals Inc., Lehi, Utah
University Hospital Bonn, Bonn, Germany
The University of North Carolina at Chapel Hill Eshelman
School of Pharmacy, Chapel
The University of Western Australia, Perth, Western Australia, Australia